Thus, among the drugs that have reached clinical use or at least clinical trials to abort or prevent attacks of HAE, a first therapeutic option is to replace the missing protein, by infusing plasma-derived C1-INH (Berinert®, Cinryze®, and Haegarda®), or recombinant C1-INH (Ruconest®) [32]. Here, SERPING1 is linked to hereditary angioedema.